Peptide therapy TikTok claims: what the science actually supports

What did @davidofloxly actually say?

The creator shared a personal story about someone close to him developing appendicitis while on a GLP-1 medication. She had localized, non-moving abdominal pain that turned out to be an inflamed appendix requiring emergency surgery. He credits quick thinking for preventing a rupture, and then extrapolates to a broader warning: GLP-1 drugs slow gastric emptying, which can cause constipation, and he believes this contributed to the appendicitis. He also says an ER doctor told him there has been "an uptick in cases" linked to GLP-1 use. His advice is to take fiber, use digestive bitters, and keep your bowels moving regularly while on these medications.

To his credit, the warning to seek emergency care for persistent, localized abdominal pain is genuinely good advice. The rest gets messier.

Does the science back this up?

The gastric emptying connection is real. The leap to appendicitis causation is not well-supported. GLP-1 receptor agonists do slow gastrointestinal motility, and this is well-documented. But the biological pathway from "slow gut" to "appendix inflammation" is not straightforward, and the evidence tying GLP-1 drugs specifically to appendicitis is thin and contested.

A 2023 observational study published in JAMA Internal Medicine (Sodhi et al.) found that semaglutide and liraglutide were associated with significantly higher rates of several GI adverse events, including ileus, and to a lesser degree bowel obstruction, compared to other weight-loss treatments. Appendicitis was not among the primary outcomes flagged. A separate 2024 pharmacovigilance analysis in Drug Safety (Faillie et al.) looked at GLP-1 class adverse event reports and noted signals for pancreatitis and gallbladder disease, with appendicitis appearing as a low-frequency reported event but without a clear causal mechanism established. The FDA label for semaglutide does not list appendicitis as a known risk. An ER physician noting an "uptick" is not the same as peer-reviewed evidence of causation.

What did they get wrong (or right)?

He got the physiology partially right and the clinical advice accidentally right. "Slowing of gastric emptying" is accurate for GLP-1 receptor agonists, and constipation is a real, common side effect. His advice to maintain fiber intake and regular bowel habits is consistent with clinical guidance for patients on these medications.

Where he goes wrong is the causal chain. He implies that constipation from GLP-1 use directly caused or contributed to the appendicitis. Appendicitis is most commonly caused by obstruction of the appendiceal lumen, often by a fecalith (hardened stool), lymphoid hyperplasia, or sometimes a foreign body. While severe constipation theoretically could increase fecalith formation, the connection between GLP-1 use and appendiceal obstruction is speculative, not established. Correlation in an ER doctor's anecdotal observation is not causation. He also self-corrects on pancreas at the end, which is worth noting, because pancreatitis is an actual FDA-labeled risk for GLP-1 drugs and probably deserved more attention than appendicitis in this video.

What should you actually know?

If you are taking a GLP-1 medication, there are real gastrointestinal risks worth knowing. Nausea, vomiting, and constipation are among the most commonly reported side effects, affecting a meaningful percentage of users. The Sodhi et al. 2023 JAMA Internal Medicine analysis found semaglutide users had roughly 9.09 times higher odds of ileus compared to bupropion-naltrexone users. Gallbladder disease, including cholecystitis, is also a labeled risk and appears with greater frequency in clinical trial data.

Persistent, localized abdominal pain that does not resolve or move is always a reason to seek emergency evaluation, regardless of what medications you are taking. That part of the video is correct and worth repeating. The creator's instinct to go to the ER was right. The lesson is not specifically about GLP-1 drugs, it is about not ignoring abdominal symptoms. Fiber supplementation and hydration are reasonable supportive measures for constipation on GLP-1 therapy, but "sour-sauve bitters" is not a clinically validated intervention and should not be treated as equivalent to medical management of GI side effects. Talk to a prescribing clinician if you are experiencing significant constipation or pain on any GLP-1 medication.